NPM1 and acute myeloid leukemia: Several hits were subsequently validated based on their ability to bind and stabilize full length NPM and a C-terminal domain carrying AML-linked mutations, and their effect on human cells expressing YFP-tagged AML-related NPM mutants has been assessed.